Table 2 Clinical characteristics of RSV-positive infants, categorised by disease severity

Total number of patients

37

25

40

 TREC during RSV infection, number of patients

13

10

24

 TREC in neonatal screening cards, number of patients

32

24

29

Age when RSV diseased - months, median (IQR)

3

(1–6)

3

(1–5.5)

2

(1–4)

p = 0.4^a

Male gender, number (%)

14

(38%)

14

(56%)

17

(43%)

p = 0.4^b

Weight - grams, mean (SD)

6522

(2277)

6748

(1935)

5974

(2065)

p = 0.4^c

Duration of symptoms at admission - days, median (IQR)

4

(3–5.25)

4

(3.5–5)

4

(3–5)

p = 0.9^a

Admission, number (%)

20

(54%)

25

(100%)

40

(100%)

Length of stay, median (IQR)

1

(0–1)

1

(1–3)

4

(2.5–5.5)

p < 0.0001^d

Length of stay > 3 days, number (%)

1

(3%)

3

(12%)

24

(62%)

p < 0.0001^e

 SpO₂ - % on admission, mean (SD)

97.4

(2.6)

97.9

(2.3)

94.7

(4.5)

p < 0.0001^c

 Respiratory rate /min on admission, mean (SD)

49

(12)

58

(12)

57

(10)

p = 0.002^c

 Respiratory rate score (max. 8), median (IQR)

2

(0.75–4.25)

4

(2.5–6)

4

(2–6)

p = 0.007^a

p = 0.4^d

 Retraction score (max. 9), median (IQR)

1

(0–2)

4

(2.25–6)

2

(1–4)

p < 0.0001^a

p = 0.003^d

 Wheeze score (max. 8), median (IQR)

0

(0–3)

5

(4–6)

2

(0–4)

p < 0.0001^a

p = 0.0002^d

 m-RDAI, median (IQR)

6

(2–8)

13

(10.5–16)

8

(6–11)

p < 0.0001^a

p < 0.0001^d

 Fluid supplement, number (%)

16

(40%)

  Intravenous fluids, number (%)

4

(10%)

  Nasogastric fluid, number (%)

14

(35%)

 Oxygen supplement, number (%)

35

(88%)

 CPAP, number (%)

4

(10%)

 Respirator, number (%)

0

(0%)